Transcode Therapeutics Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

RNAZ$1.35-12.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2023 and 2022

BALANCE SHEETS


· · December 31, · · December 31,
· 2023 · 2022
Assets · ·
Current assets: · ·
Cash	$2,767,598	$4,968,418
Grant receivable	—	360,229
Prepaid expenses and other current assets	1,687,846	2,050,758
Total current assets	4,455,444	7,379,405
Property and equipment, net of depreciation	120,707	208,581
Right-of-use asset, net of amortization	481,694	—
Security deposit	111,856	—
Total assets	$5,169,701	$7,587,986

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$3,051,259	$4,347,290
Deferred grant income	27,057	—
Short-term lease liability	412,280	—
Total current liabilities	3,490,596	4,347,290
Long-term lease liability	38,291	—
Total liabilities	3,528,887	4,347,290
Stockholders’ equity:
Preferred stock – $0.0001 par value; 10,000,000 authorized at December 31, 2023 and 2022; - 0 - shares issued and outstanding at December 31, 2023 and 2022	—	—
Common stock – $0.0001 par value, 290,000,000 shares authorized at December 31, 2023 and 2022; 627,448 and 16,222 shares issued and outstanding at December 31, 2023 and 2022, respectively	63	2
Additional paid-in capital	48,057,095	31,110,943
Accumulated deficit	(46,416,344)	(27,870,249)
Total stockholders’ equity	1,640,814	3,240,696
Total liabilities and stockholders’ equity	$5,169,701	$7,587,986

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.